FindTrial
Sign In

Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

A Randomized Study Comparing Combined Vitrectomy and Triamcinolone to Laser Grid in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00642226
Enrollment
34
Registered
2008-03-24
Start date
2006-11-30
Completion date
2013-11-30
Last updated
2014-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Branch Retinal Vein Occlusion, Macular Edema

Keywords

Branch Retinal Vein Occlusion, BRVO, Macular Edema, Triamcinolone, Vitrectomy

Brief summary

The purpose of this study is to determine whether pars plana vitrectomy in combination with triamcinolone acetate is effective in the treatment of macular edema due to branch retinal vein occlusion.

Interventions

PROCEDUREGrid Laser

ETDRS Grid Laser

PROCEDUREVitrectomy and 20 mg triamcinolone

Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate

Sponsors

Helse Stavanger HF
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Macular edema secondary to BRVO * Best Corrected Visual Acuity of ≤ 20/40 on ETDRS chart * Duration no shorter than 3 months * Duration no longer than 12 months

Exclusion criteria

* Proliferations in study eye * Blod in vitreous cavity * Previous fundus laser treatment * BRVO with over 180˚ of ischemia on FA * Age under 18 * Other eye condition which contribute to relevant loss of visual acuity

Design outcomes

Primary

MeasureTime frame
Visual acuity (ETDRS)12 and 36 Months

Secondary

MeasureTime frame
Retinal thickening measured on OCT.12 and 36 Months

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026